Funds Managed by Lions Capital Acquire Additional Interest in

Urodynamix Technologies

VANCOUVER, British Columbia, July 26, 2007 - Lions Capital Corp. announced today, in accordance with regulatory requirements, that it has acquired control and direction over an additional interest in Urodynamix Technologies Ltd. via its funds under management. Lions Capital is the fund manager for BC Advantage Funds (VCC) Ltd. ("Advantage") and Lions Liquidity Investment Fund I Limited Partnership ("Lions Fund").

Advantage has acquired an additional 3,333,000 common shares of Urodynamix by exercising share purchase warrants, in accordance with their terms, for an aggregate price of $666,600. Advantage previously acquired 6,666,000 common shares of Urodynamix on August 8, 2005 and 6,666,000 common shares of Urodynamix on July 25, 2006. In total, Advantage previously held 13,332,000 common shares of Urodynamix, constituting approximately 19.6% of the current issued and outstanding shares of Urodynamix. Advantage now holds 16,665,000 common shares of Urodynamix, constituting approximately 21.7% of the current issued and outstanding shares of Urodynamix.

In addition, Lions Fund has acquired a total of 1,449,000 common shares of Urodynamix for an aggregate price of $342,250. Lions Fund did not previously own any interest in Urodynamix. Lions Fund acquired an aggregate of 949,000 common shares of Urodynamix from a total of three persons in transactions conducted using the facilities of the TSX Venture Exchange. Lions Fund also acquired 500,000 common shares of Urodynamix from another Urodynamix shareholder for $105,000 in a transaction that did not use the facilities of the TSX Venture Exchange. No special terms or conditions applied to such acquisitions by Lions Fund.

Following the share acquisitions, Lions Capital now has control and direction over a total of 18,114,000 common shares in Urodynamix, which constitutes approximately 23.5% of the current issued and outstanding shares.

The share acquisitions by funds managed by Lions Capital is for investment purposes. In connection with Advantage's acquisition of common shares of Urodynamix on August 15, 2005, Advantage provided an undertaking to the TSX Venture Exchange not to exercise voting rights it may from time to time have on shares of Urodynamix representing more than 19.9% of the outstanding voting shares of Urodynamix until the earlier of (1) the day on which the TSX Venture Exchange provides written confirmation that Advantage is released from the undertaking and (2) the day Urodynamix receives shareholder approval to permit Advantage to exercise voting rights on shares representing more than 19.9% of the outstanding voting shares of Urodynamix.

L I O N S   C A P I T A L   C O R P .

Suite 1280 - 885 West Georgia Street, Vancouver, BC V6C 3E8

Phone: 604-688-6877  E-Mail: Info@lionscapital.com

About Urodynamix Technologies Ltd.

Urodynamix is developing a portfolio of non-invasive diagnostic products for a variety of large and growing global markets. The Company is currently developing NIRS applications for urological conditions in men and women, intra-abdominal hypertension and compartment syndrome, erectile dysfunction and vascular diseases. The Company’s disruptive technology has the potential to affect the diagnosis and treatment of more than 200 million people worldwide.

For further information, please contact:

Craig Pamplin, PhD, CFA

Director, Corporate Development and Communications

Urodynamix Technologies Ltd.

Tel: (604) 638-0247

Email: cpamplin@urodynamix.com

www.urodynamix.com